The Meso-Kit-Infuser
Infusion for the 3rd millennium
Mesoperfusion using the meso-kit-infusor was developed in 1995 by Dr Jacques Strouk (biomedical pharmacist based in Marseille) and Dr Bernard Guez. It represents infusion for the 3rd millennium, adopting the subcutaneous route often in replacement of classical intravenous infusion (see Medical research perspectives in hydrotomy).
Currently, the multi-outlet “octopus” meso-kit-infusor uses 12, 18 or 24 needles to allow treatment at the structural and fundamental levels to be delivered to very large areas or even the whole spine (to treat osteoporosis or vertebral compression fractures). Treatment with this system avoids many side effects.
Therapeutic advantages
Mesoperfusion primarily uses the local or locoregional route to provide immediate direct action (“in situ”) on the targeted area, circumventing degradation or metabolisation of the drugs’ active ingredients, preventing hepatic and renal overload as well as avoiding the gastric, neurological or myocardial toxicity of certain products. With mesoperfusion, the first filter layer is the skin with the lesion in the foreground. From a technical point of view, the “practical” advantages of mesoperfusion should be highlighted: no need to look for a “good” vein, easy to remove (even by the patient’s family) at the end of treatment. These advantages make it possible to “amplify” the percutaneous hydrotomy process over time, increasing its effectiveness in complicated disorders. Percutaneous hydrotomy could thus constitute the future of treatment for various specialized pathologies: hydration of geriatric patients, spinal stenosis, post-operative fibrosis, progressive osteoarthritis with vertebral collapse, vascular degeneration, shingles, kidney failure, Crohn’s disease, colonopathy, severe burn victims, cosmetic medicine (cellulite), etc.
See Technical documentation for the use of the meso-kit-infuser
Multi-point subcutaneous infusion device (12 outlets) available from MESALYSE (https://www.aestheticgroup.fr/fr/28-mesoperfusion)